The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-23. Anything still debated is marked as such rather than presented as settled.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
This shows that the female mealworm beetles consistently preferred males that invested significantly less in immune system recovery, and that males are not able to allocate resources simultaneously both to improving their health or, in this case, recovery of their immune system, and to increasing their sexual attractiveness.
Catatonia is a neuropsychiatric syndrome most commonly seen in people with underlying mood disorders such as major depressive disorder, or psychotic disorders such as schizophrenia. People with catatonia exhibit abnormal movement and behaviors that vary from person to person, and which may fluctuate in intensity within a single episode. People with catatonia appear withdrawn, with limited interaction with the outside world and difficulty processing information. They may be nearly motionless for days on end or perform repetitive, purposeless movements. People may exhibit very different sets of behaviors and still be diagnosed with catatonia. Treatment with benzodiazepines or electroconvulsive therapy is most effective and leads to remission of symptoms in most cases. There are different subtypes of catatonia, which represent groups of symptoms that commonly occur together. These include stuporous/akinetic catatonia, excited catatonia, malignant catatonia, and periodic catatonia. Catatonia has historically been related to schizophrenia, but is most often seen in mood disorders. It is now known that catatonic symptoms are nonspecific and may occur in other mental, neurological, and medical conditions. The prognosis of catatonia is typically good, with complete remission in some patients; however, outcomes vary depending on the underlying disorder.
Mohammed Brighieth, a professor at Birzeit University, warned of the psychological impact of the war on children, stating, "The children of Gaza live somewhere between the process of psychological trauma and certain death." A 5-year-old whose entire immediate family was killed by an Israeli airstrike while evacuating to Rafah, was described as being starkly different by his grandmother, he was reportedly in shock, does not talk much, and was scared of any sounds. Parents in Rafah purchased songbirds for their children to help them cope with the constant sounds of bombing. On 21 February 2024, the chair of the Norwegian Refugee Council warned that all children in Gaza would likely suffer from trauma due to the war. On 23 February 2024, the director of Doctors Without Borders reported, "Psychological injuries have led children as young as five to tell us that they would prefer to die." Save the Children found, "Children in Gaza are going through a period of mass-scale shock and grief. This war and the physical and mental scars it is leaving on children is further eroding their resilience." In July 2024, Julia Wendt, the emergency child protection coordinator with the International Rescue Committee, stated children in Gaza were suffering from nightmares and bedwetting due to the mental toll of the war. In September 2024, children's hair was turning prematurely grey due to their high levels of stress. In October 2024, Dr.
== Etymology == The word sirloin derives from the Middle English surloine, itself derived from the Old French word surloigne (variant of surlonge), that is, sur for 'above' and longe for 'loin'. Therefore, a sirloin is the cut from above the loin. In Modern French, the cut of meat is called aloyau or faux-filet. A fictitious etymology recounts that a king of England knighted the loin of beef as "Sir Loin." Although the pun is reported as early as 1630, and the notion of a king knighting it dates to 1655, the name predates any of the many kings (Henry VIII, James VI and I, Charles II) mentioned in versions of the anecdote. The story at most influenced the spelling sir rather than sur.
The coexistence of intense, divergent moods within an individual was recognized by Homer, Hippocrates, and Aretaeus, the last describing the vacillating presence of impulsive anger, melancholia, and mania within a single person. Swiss physician Théophile Bonet revived the concept in 1684, and used the term folie maniaco-mélancolique to describe the phenomenon of unstable moods that followed an unpredictable course. Other writers noted the same pattern, including the American psychiatrist Charles H. Hughes in 1884 and J. C. Rosse in 1890, who called the disorder "borderline insanity". In 1921, Emil Kraepelin identified an "excitable personality" that closely parallels the borderline features outlined in the current concept of BPD. The idea that there were forms of disorder that were neither psychotic nor simply neurotic began to be discussed in psychoanalytic circles in the 1930s. The first formal definition of borderline disorder is widely acknowledged to have been written by Adolph Stern in 1938. He described a group of patients who he felt to be on the borderline between neurosis and psychosis, who often came from family backgrounds marked by trauma. He argued that such patients would often need more active support than that provided by classical psychoanalytic techniques. The 1960s and 1970s saw a shift from thinking of the condition as borderline schizophrenia to thinking of it as a borderline affective disorder (mood disorder), on the fringes of bipolar disorder, cyclothymia, and dysthymia.
Sources: en.wikipedia.org
Faculty of Biotechnology Faculty of Chemistry Faculty of Philology Faculty of Physics and Astronomy Faculty of Mathematics and Computer Science Faculty of Biological Sciences Faculty of History and Pedagogy Faculty of Earth and Environmental Sciences Faculty of Social Sciences Faculty of Law, Administration and Economics
Ceruloplasmin is the major copper-carrying protein in the blood. Ceruloplasmin exhibits oxidase activity, which is associated with possible oxidation of Fe(II) into Fe(III), therefore assisting in its transport in the blood plasma in association with transferrin, which can carry iron only in the Fe(III) state.
=== Type III === A civilization with energy on the scale of its own galaxy, with an energy consumption of ≈4×1044 erg/s. Lemarchand defined civilizations of this type as having access to energy comparable to the luminosity of the entire Milky Way galaxy, about ≈4×1044 erg/s" (≈4×1037 watts). In accordance with the data available at the time, Kardashev did not go beyond a Type III civilization. However, new types (0, IV, V, and VI) have been proposed.
== External links == International Chemical Safety Card 0095 NIOSH Pocket Guide to Chemical Hazards. "#0017". National Institute for Occupational Safety and Health (NIOSH). Institut national de recherche et de sécurité (2004). "Alcool allylique". Fiche toxicologique n° 156 (in French). Paris: INRS. State of Michigan public information on allyl alcohol Occupational exposure guidelines
Sources: en.wikipedia.org
domain A discrete, usually contiguous region of a protein (or the corresponding amino acid sequence of a polypeptide) which serves a particular function or is defined by particular physico-chemical properties (e.g. hydrophobic, polar, non-polar, globular, etc.), and especially one which folds independently of the rest of the polypeptide into a characteristic, self-stabilizing spatial conformation as part of the protein's supersecondary structure and which contributes to or defines its biological activity. Large proteins are generally composed of multiple domains linked by short, intervening non-domain sequences. Domains are commonly grouped into classes with similar properties or functions, e.g. DNA-binding domains. More broadly, the term may also be used to refer to a discrete structural entity within any biomolecule, including functionally or compositionally distinct subregions of nucleic acid sequences and chromosomes.
Biosynthesis of morphine in the opium poppy begins with two tyrosine derivatives, dopamine and 4-hydroxyphenylacetaldehyde. Condensation of these precursors yields the primary intermediate higenamine (norcoclaurine). Subsequent action of four enzymes yields the tetrahydroisoquinoline reticuline, which is converted into salutaridine, thebaine, and oripavine. The enzymes involved in this process are the salutaridine synthase, salutaridine:NADPH 7-oxidoreductase and the codeinone reductase. Researchers are attempting to reproduce the biosynthetic pathway that produces morphine in genetically engineered yeast. In June 2015 the S-reticuline could be produced from sugar and R-reticuline could be converted to morphine, but the intermediate reaction could not be performed. In August 2015 the first complete synthesis of thebaine and hydrocodone in yeast was reported, but the process would need to be 100,000 times more productive to be suitable for commercial use.
=== Breast cancer === Keratin constitutes a large multigene family known as cytokeratins. These cytokeratins are differentially expressed across various epithelial types and have been extensively studied as markers for breast cancer. They are categorized into acidic type I and basic-to-neutral type II cytokeratins. The intermediate filament network is formed by the necessary pairing of equal amounts of type I and type II keratins. While hair keratins, such as KRT81, are typical in hard-keratinized structures like hair and nails, they are thought to serve as structural proteins specific to these organs without expression elsewhere, such as the mammary gland. KRT81, a type II hair keratin, is a major hair protein expressed in the hair cortex. Despite being typically associated with hair structures, KRT81 expression has been observed in the SKBR3 human breast cancer cell line and metastatic lymph nodes of breast carcinomas, but not in normal breast epithelial cells. Moreover, the expressed KRT81 was found to be a 5′-truncated isoform (ΔHb1), with the full-length protein not being expressed. However, the exact function of this truncated form in breast cancer cells remains unclear. Western blot analysis detected the presence of the complete 55-kDa KRT81 in various human breast cancer cell lines (MCF7, SKBR3, MDA-MB-231), normal human mammary epithelial cells (HMEC), and non-neoplastic cells (MCF10A). Reverse transcription-polymerase chain reaction confirmed the expression of the full-length KRT81, encompassing its 5' region, in breast cells.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.